A Phase 2b Randomised, Double-blind, Placebo-controlled, Parallel, Adaptive 2-Stage, Multi-Centre Study to Evaluate the Safety and Efficacy of Oral PTG-100 Induction in Subjects With Moderate to Severe Active Ulcerative Colitis

Trial Profile

A Phase 2b Randomised, Double-blind, Placebo-controlled, Parallel, Adaptive 2-Stage, Multi-Centre Study to Evaluate the Safety and Efficacy of Oral PTG-100 Induction in Subjects With Moderate to Severe Active Ulcerative Colitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs PTG 100 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Protagonist Therapeutics
  • Most Recent Events

    • 08 Aug 2017 According to a Protagonist Therapeutics media release, the interim analysis is now expected in early 2018; top-line results are still anticipated for the second half of 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 18 Jan 2017 Planned End Date changed from 1 May 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top